Skip to content

Phase 2 Study of ART0380 Plus Gemcitabine in Platinum-Resistant Ovarian Cancers Begins

| Media coverage

A phase 2 study of ART0380 in combination with gemcitabine for the treatment of platinum-resistant ovarian cancer has been initiated (NCT04657068).1

ART0380 is a potential best-in-class oral, highly potent, and selective ATR inhibitor. ATR inhibition can regulate DNA replication stress response, promoting apoptosis. The agent is being evaluated as monotherapy and in combination with other agents for the treatment of solid tumors.

To read more: